About Arbutus Biopharma
Arbutus Biopharma is a company based in Burnaby (Canada) founded in 1992. It operates as a HealthTech. Arbutus Biopharma has raised $10 million across 5 funding rounds from investors including Roivant Sciences, Alnylam and Roche. The company has 44 employees as of December 31, 2024. Arbutus Biopharma has completed 2 acquisitions, including OnCore Biopharma and Protiva Biotherapeutics. Arbutus Biopharma offers products and services including Imdusiran (AB-729) and AB-101. Arbutus Biopharma operates in a competitive market with competitors including Insitro, BridgeBio, Adaptive Biotechnologies, Moderna and ATAI, among others.
- Headquarter Burnaby, Canada
- Employees 44 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Arbutus Biopharma Corporation
-
Annual Revenue
$6.17 M-65.98as on Dec 31, 2024
-
Net Profit
$-69.92 M4.02as on Dec 31, 2024
-
EBITDA
$-68.59 M10.49as on Dec 31, 2024
-
Total Equity Funding
$10 M (USD)
in 5 rounds
-
Latest Funding Round
$55 M (USD), Post-IPO
Dec 13, 2021
-
Investors
Roivant Sciences
& 4 more
-
Employee Count
44
as on Dec 31, 2024
-
Investments & Acquisitions
OnCore Biopharma
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Arbutus Biopharma
Arbutus Biopharma is a publicly listed company on the NASDAQ with ticker symbol ABUS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Arbutus Biopharma
Arbutus Biopharma offers a comprehensive portfolio of products and services, including Imdusiran (AB-729) and AB-101. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
RNAi therapeutic developed for chronic HBV treatment success.
Asset developed to support HBV treatment and cure.
Unlock access to complete
Unlock access to complete
Funding Insights of Arbutus Biopharma
Arbutus Biopharma has successfully raised a total of $10M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $55 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $55.0M
- First Round First Round
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2021 | Amount | Post-IPO - Arbutus Biopharma | Valuation |
investors |
|
| Jan, 2018 | Amount | Post-IPO - Arbutus Biopharma | Valuation |
investors |
|
| Sep, 2017 | Amount | Post-IPO - Arbutus Biopharma | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Arbutus Biopharma
Arbutus Biopharma has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include Roivant Sciences, Alnylam and Roche. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
APIs and intermediates are developed and manufactured for pharmaceuticals.
|
Founded Year | Domain | Location | |
|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
Founded Year | Domain | Location | |
|
RNA interference-based therapeutics are developed for multiple disorders.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Arbutus Biopharma
Arbutus Biopharma has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include OnCore Biopharma and Protiva Biotherapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapies for the treatment of chronic hepatitis B virus (HBV) infection
|
2012 | ||||
|
Nucleic acid-based therapeutics are developed for treating various diseases.
|
2000 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Arbutus Biopharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Arbutus Biopharma Comparisons
Competitors of Arbutus Biopharma
Arbutus Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, Adaptive Biotechnologies, Moderna and ATAI, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Arbutus Biopharma
Frequently Asked Questions about Arbutus Biopharma
When was Arbutus Biopharma founded?
Arbutus Biopharma was founded in 1992 and raised its 1st funding round 10 years after it was founded.
Where is Arbutus Biopharma located?
Arbutus Biopharma is headquartered in Burnaby, Canada. It is registered at Burnaby, British Columbia, Canada.
Is Arbutus Biopharma a funded company?
Arbutus Biopharma is a funded company, having raised a total of $10M across 5 funding rounds to date. The company's 1st funding round was a Post-IPO of $50M, raised on Jun 01, 2002.
How many employees does Arbutus Biopharma have?
As of Dec 31, 2024, the latest employee count at Arbutus Biopharma is 44.
What is the annual revenue of Arbutus Biopharma?
Annual revenue of Arbutus Biopharma is $6.17M as on Dec 31, 2024.
What does Arbutus Biopharma do?
Arbutus Biopharma is engaged in developing innovative virology solutions, with a primary focus on hepatitis B virus (HBV) treatments. The companys pipeline includes clinical assets like Imdusiran (AB-729), an RNAi therapeutic aimed at achieving functional cures for chronic HBV through combination therapies. Efforts are directed towards a multi-faceted approach involving suppression of viral DNA, reduction of viral antigens, and boosting immune responses. The portfolio is supported by a team with deep scientific and commercial expertise, targeting unmet medical needs in the virology sector.
Who are the top competitors of Arbutus Biopharma?
Arbutus Biopharma's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Arbutus Biopharma offer?
Arbutus Biopharma offers Imdusiran (AB-729) and AB-101.
Is Arbutus Biopharma publicly traded?
Yes, Arbutus Biopharma is publicly traded on NASDAQ under the ticker symbol ABUS.
How many acquisitions has Arbutus Biopharma made?
Arbutus Biopharma has made 2 acquisitions, including OnCore Biopharma, and Protiva Biotherapeutics.
Who are Arbutus Biopharma's investors?
Arbutus Biopharma has 5 investors. Key investors include Roivant Sciences, Alnylam, Roche, BDC, and Qilu Pharmaceutical Group.
What is Arbutus Biopharma's ticker symbol?
The ticker symbol of Arbutus Biopharma is ABUS on NASDAQ.